Novel analogs of VIP with multiple C-terminal domains

[1]  P. de Neef,et al.  Addition of the (28-38) peptide sequence of PACAP to the VIP sequence modifies peptide selectivity and efficacy. , 2009, International journal of peptide and protein research.

[2]  I. Gozes,et al.  Novel extended and branched N-terminal analogs of VIP , 2006, Regulatory Peptides.

[3]  A. Couvineau,et al.  Peptide Agonist Docking in the N-terminal Ectodomain of a Class II G Protein-coupled Receptor, the VPAC1 Receptor , 2006, Journal of Biological Chemistry.

[4]  P. Robberecht,et al.  Contribution of the Carboxyl Terminus of the VPAC1 Receptor to Agonist-induced Receptor Phosphorylation, Internalization, and Recycling* , 2005, Journal of Biological Chemistry.

[5]  R. Riek,et al.  NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[6]  S. Onoue,et al.  Alpha-helical structure in the C-terminus of vasoactive intestinal peptide: functional and structural consequences. , 2004, European journal of pharmacology.

[7]  A. Couvineau,et al.  Photoaffinity Labeling Demonstrates Physical Contact between Vasoactive Intestinal Peptide and the N-terminal Ectodomain of the Human VPAC1 Receptor* , 2003, Journal of Biological Chemistry.

[8]  E. Goetzl,et al.  A Lymphocyte-Generated Fragment of Vasoactive Intestinal Peptide with VPAC1 Agonist Activity and VPAC2 Antagonist Effects , 2003, Journal of Pharmacology and Experimental Therapeutics.

[9]  C. Pan,et al.  Generation of Highly Selective VPAC2 Receptor Agonists by High Throughput Mutagenesis of Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-activating Peptide* , 2003, The Journal of Biological Chemistry.

[10]  Illana Gozes,et al.  VIP and drug design. , 2003, Current pharmaceutical design.

[11]  A. Couvineau,et al.  Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP , 2002, Regulatory Peptides.

[12]  Andrea Bernini,et al.  A branched peptide mimotope of the nicotinic receptor binding site is a potent synthetic antidote against the snake neurotoxin alpha-bungarotoxin. , 2002, Biochemistry.

[13]  T. Moody,et al.  VIP-ellipticine derivatives inhibit the growth of breast cancer cells. , 2002, Life sciences.

[14]  R. Jensen,et al.  Elucidation of vasoactive intestinal peptide pharmacophore for VPAC(1) receptors in human, rat, and guinea pig. , 2002, The Journal of pharmacology and experimental therapeutics.

[15]  A. Thomas,et al.  The Human VPAC1 Receptor , 2001, The Journal of Biological Chemistry.

[16]  J. Fahrenkrug,et al.  Creation of a selective antagonist and agonist of the rat VPAC(1) receptor using a combinatorial approach with vasoactive intestinal peptide 6-23 as template. , 2000, Molecular pharmacology.

[17]  Annick Thomas,et al.  Identification of Key Residues for Interaction of Vasoactive Intestinal Peptide with Human VPAC1 and VPAC2Receptors and Development of a Highly Selective VPAC1Receptor Agonist , 2000, The Journal of Biological Chemistry.

[18]  I. Gozes,et al.  Pharmaceutical VIP: prospects and problems. , 1999, Current medicinal chemistry.

[19]  O. Ashur-Fabian,et al.  Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: neuroprotective drug design. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[20]  P. de Neef,et al.  Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors. , 1998, European journal of pharmacology.

[21]  S. Rawlings,et al.  International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. , 1998, Pharmacological reviews.

[22]  O. Ashur-Fabian,et al.  Identification of VIP/PACAP receptors on rat astrocytes using antisense oligodeoxynucleotides , 1997, Journal of Molecular Neuroscience.

[23]  B. Wulff,et al.  The C‐terminal part of VIP is important for receptor binding and activation, as evidenced by chimeric constructs of VIP/secretin , 1997, FEBS letters.

[24]  Y. Cao,et al.  Photoaffinity labeling analysis of the interaction of pituitary adenylate-cyclase-activating polypeptide (PACAP) with the PACAP type I receptor. , 1997, European journal of biochemistry.

[25]  J. Vilardaga,et al.  The C-terminus ends of secretin and VIP interact with the N-terminal domains of their receptors , 1996, Peptides.

[26]  A. Couvineau,et al.  Receptors for VIP, PACAP, Secretin, GRF, Glucagon, GLP‐1, and Other Members of Their New Family of G Protein‐Linked Receptors: Structure‐Function Relationship with Special Reference to the Human VIP‐1 Receptor a , 1996, Annals of the New York Academy of Sciences.

[27]  S. Wank,et al.  Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[28]  H. Foda,et al.  Pituitary adenylate cyclase-activating peptide (PACAP), a VIP-like peptide, has prolonged airway smooth muscle relaxant activity , 1991, Peptides.

[29]  T. Moody,et al.  An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system. , 1991, The Journal of pharmacology and experimental therapeutics.

[30]  S. Said.  Vasoactive intestinal polypeptide biologic role in health and disease , 1991, Trends in Endocrinology & Metabolism.

[31]  Y. Thériault,et al.  Structural determination of the vasoactive intestinal peptide by two‐dimensional 1H‐nmr spectroscopy , 1991, Biopolymers.

[32]  I. Gozes,et al.  Vasoactive intestinal peptide potentiates sexual behavior: Inhibition by novel antagonist , 1989, Regulatory Peptides.

[33]  D. Fry,et al.  Solution structure of an analogue of vasoactive intestinal peptide as determined by two-dimensional NMR and circular dichroism spectroscopies and constrained molecular dynamics. , 1989, Biochemistry.

[34]  A. Fournier,et al.  Conformational Analysis of Vasoactive Intestinal Peptide and Related Fragments a , 1988, Annals of the New York Academy of Sciences.

[35]  P. Anand,et al.  Marked depletion of dorsal spinal cord tachykinins and CGRP with intact skin flares in patients with the Shy-Drager syndrome , 1986, Regulatory Peptides.

[36]  J. T. Turner,et al.  A fragment of vasoactive intestinal peptide, VIP(10–28), is an antagonist of VIP in the colon carcinoma cell line, HT29 , 1986, Peptides.

[37]  A. Couvineau,et al.  Structural requirements for VIP interaction with specific receptors in human and rat intestinal membranes: effect of nine partial sequences. , 1984, Biochemical and biophysical research communications.

[38]  K. Weber,et al.  Dissoziation der Rinderleber-Katalase in ihre Untereinheiten , 1967 .

[39]  I. Gozes,et al.  VIP: Molecular biology and neurobiological function , 2007, Molecular Neurobiology.

[40]  V. Lelièvre,et al.  Differential expression and function of PACAP and VIP receptors in four human colonic adenocarcinoma cell lines. , 1998, Cellular signalling.

[41]  R. Sheppard,et al.  Solid phase peptide synthesis : a practical approach , 1989 .